patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_932531 | REC_0007601 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 14 | 6.5 | 60 | male | 0 | 39 | 5.1 | 0 | pembrolizumab 200 mg q3w | 45.4 | false | MSS | 2026-03-15T05:35:58.717321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910005 | REC_0007602 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 6.8 | 75 | female | 2 | 9 | 4.5 | 3 | alectinib 600 mg BID | 12.4 | true | MSS | 2026-03-15T05:35:58.717571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534863 | REC_0007603 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.9 | 66 | female | 1 | 18 | 6.4 | 7 | sotorasib 960 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:58.717825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983363 | REC_0007604 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 7 | 68 | female | 0 | 11 | 5.2 | 5 | osimertinib 80 mg daily | 17.3 | false | MSS | 2026-03-15T05:35:58.718069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836126 | REC_0007605 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 9.7 | 75 | female | 2 | 15 | 5.6 | 6 | pembrolizumab 200 mg q3w | 22 | false | MSS | 2026-03-15T05:35:58.718322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190063 | REC_0007606 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 14.6 | 61 | male | 0 | 2 | 3.9 | 5 | osimertinib 80 mg daily | 10.7 | true | MSI-H | 2026-03-15T05:35:58.718718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621200 | REC_0007607 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 16.3 | 74 | female | 1 | 10 | 6.1 | 8 | entrectinib 600 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:58.718968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835927 | REC_0007608 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 9.7 | 65 | male | 1 | 14 | 5.6 | 0 | entrectinib 600 mg daily | 22.6 | true | MSS | 2026-03-15T05:35:58.719204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927900 | REC_0007609 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 19 | 13.4 | 53 | male | 0 | 9 | 5.1 | 0 | osimertinib 80 mg daily | 30.3 | true | MSS | 2026-03-15T05:35:58.719440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558092 | REC_0007610 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.5 | 54 | male | 0 | 29 | 3.6 | 4 | sotorasib 960 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:35:58.719675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797911 | REC_0007611 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 6.2 | 58 | male | 0 | 12 | 6.5 | 2 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:58.719909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629412 | REC_0007612 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 35 | 15.4 | 58 | female | 1 | 11 | 4.6 | 2 | osimertinib 80 mg daily | 24.9 | false | MSS | 2026-03-15T05:35:58.720199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731611 | REC_0007613 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 31 | 11.9 | 83 | female | 1 | 15 | 6.9 | 0 | osimertinib 80 mg daily | 43.4 | true | MSI-H | 2026-03-15T05:35:58.720440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896516 | REC_0007614 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 5 | 59 | female | 0 | 22 | 7.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:58.720675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109244 | REC_0007615 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 14.4 | 67 | female | 0 | 21 | 4.6 | 5 | sotorasib 960 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:58.720914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622603 | REC_0007616 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 3.3 | 55 | female | 0 | 7 | 6.5 | 2 | pembrolizumab 200 mg q3w | 13.8 | true | MSS | 2026-03-15T05:35:58.721148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276012 | REC_0007617 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 12.4 | 60 | female | 1 | 8 | 6.9 | 8 | entrectinib 600 mg daily | 18.8 | true | MSI-H | 2026-03-15T05:35:58.721388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654541 | REC_0007618 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 16.7 | 72 | female | 1 | 17 | 4.4 | 1 | alectinib 600 mg BID | 30.2 | true | MSS | 2026-03-15T05:35:58.721622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673719 | REC_0007619 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 12.3 | 86 | male | 2 | 0 | 4.3 | 6 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.721914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562021 | REC_0007620 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.8 | 59 | male | 0 | 23 | 7.6 | 2 | osimertinib 80 mg daily | 24.3 | false | MSI-H | 2026-03-15T05:35:58.722158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946002 | REC_0007621 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 10.2 | 66 | female | 0 | 14 | 5.5 | 7 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.722410+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198826 | REC_0007622 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 6.5 | 85 | female | 0 | 55 | 5.4 | 1 | pembrolizumab 200 mg q3w | 25.1 | false | MSS | 2026-03-15T05:35:58.722640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521380 | REC_0007623 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.9 | 67 | female | 0 | 37 | 4 | 6 | carboplatin + paclitaxel + pembrolizumab | 18.4 | false | MSS | 2026-03-15T05:35:58.722915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414574 | REC_0007624 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 13.2 | 69 | female | 0 | 10 | 6.4 | 5 | alectinib 600 mg BID | 7 | false | MSI-H | 2026-03-15T05:35:58.723164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837229 | REC_0007625 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 11.6 | 85 | female | 2 | 17 | 4.8 | 2 | sotorasib 960 mg daily | 15.6 | true | MSS | 2026-03-15T05:35:58.723399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644998 | REC_0007626 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 7 | 55 | female | 0 | 23 | 6.2 | 3 | osimertinib 80 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:58.723630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936668 | REC_0007627 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 13.9 | 69 | female | 1 | 7 | 5.4 | 1 | pembrolizumab 200 mg q3w | 25.7 | true | MSI-H | 2026-03-15T05:35:58.723861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621933 | REC_0007628 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 4.2 | 66 | female | 0 | 16 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 29.4 | false | MSS | 2026-03-15T05:35:58.724152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714423 | REC_0007629 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.3 | 65 | female | 1 | 13 | 4 | 6 | osimertinib 80 mg daily | 8.5 | true | MSS | 2026-03-15T05:35:58.724406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457534 | REC_0007630 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.4 | 63 | male | 1 | 26 | 4 | 5 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:58.724643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203770 | REC_0007631 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 12.9 | 69 | male | 1 | 12 | 6.1 | 6 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:58.724880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992147 | REC_0007632 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 12.7 | 72 | female | 1 | 15 | 4.3 | 6 | alectinib 600 mg BID | 7.2 | false | MSI-H | 2026-03-15T05:35:58.725156+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955937 | REC_0007633 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 26 | 10 | 66 | female | 0 | 12 | 5.5 | 0 | alectinib 600 mg BID | 32.2 | false | MSS | 2026-03-15T05:35:58.725397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486359 | REC_0007634 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 8.8 | 76 | female | 2 | 58 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 26.4 | true | MSS | 2026-03-15T05:35:58.725624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795089 | REC_0007635 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 6.6 | 79 | male | 3 | 45 | 4.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:58.725860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119245 | REC_0007636 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 11.2 | 67 | male | 0 | 10 | 5.5 | 1 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:58.726095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460581 | REC_0007637 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 13.3 | 69 | female | 0 | 14 | 6.8 | 6 | sotorasib 960 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:58.726333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568043 | REC_0007638 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 15.6 | 68 | female | 0 | 18 | 6.9 | 2 | sotorasib 960 mg daily | 19.6 | true | MSI-H | 2026-03-15T05:35:58.726563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871352 | REC_0007639 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 10.7 | 81 | female | 1 | 5 | 4.2 | 2 | sotorasib 960 mg daily | 19 | false | MSS | 2026-03-15T05:35:58.726797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658490 | REC_0007640 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 8.7 | 61 | male | 1 | 16 | 4.6 | 2 | entrectinib 600 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:58.727027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799568 | REC_0007641 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 12.3 | 64 | female | 0 | 11 | 6 | 5 | osimertinib 80 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.727262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799097 | REC_0007642 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 12 | 69 | female | 0 | 16 | 3.5 | 1 | osimertinib 80 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:58.727492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348997 | REC_0007643 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 9.3 | 67 | female | 1 | 9 | 7 | 1 | alectinib 600 mg BID | 20.5 | true | MSS | 2026-03-15T05:35:58.727728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889259 | REC_0007644 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 11.1 | 64 | male | 0 | 69 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.7 | true | MSI-H | 2026-03-15T05:35:58.727962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115888 | REC_0007645 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 26 | 19.1 | 61 | female | 2 | 12 | 7.2 | 0 | osimertinib 80 mg daily | 50 | true | MSI-H | 2026-03-15T05:35:58.728268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905150 | REC_0007646 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 12.7 | 62 | male | 0 | 16 | 6.8 | 0 | osimertinib 80 mg daily | 43.2 | true | MSI-H | 2026-03-15T05:35:58.728508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392288 | REC_0007647 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 8.3 | 67 | female | 1 | 19 | 5.1 | 1 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:58.728737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895104 | REC_0007648 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 10.6 | 70 | female | 2 | 17 | 6.1 | 1 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:58.728969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737720 | REC_0007649 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9.8 | 66 | female | 0 | 17 | 6.5 | 3 | sotorasib 960 mg daily | 6.9 | true | MSS | 2026-03-15T05:35:58.729199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322785 | REC_0007650 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 15.4 | 69 | male | 1 | 32 | 5.7 | 5 | osimertinib 80 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:58.729436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268955 | REC_0007651 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.8 | 65 | male | 0 | 27 | 3.7 | 5 | pembrolizumab 200 mg q3w | 13.5 | true | MSS | 2026-03-15T05:35:58.729671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881936 | REC_0007652 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 9.1 | 68 | male | 0 | 18 | 5.7 | 1 | sotorasib 960 mg daily | 23.5 | false | MSS | 2026-03-15T05:35:58.729907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420804 | REC_0007653 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 12.5 | 61 | male | 0 | 18 | 4 | 1 | osimertinib 80 mg daily | 22.1 | false | MSS | 2026-03-15T05:35:58.730145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491454 | REC_0007654 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 9.4 | 57 | male | 1 | 11 | 4.4 | 1 | osimertinib 80 mg daily | 17 | false | MSS | 2026-03-15T05:35:58.730376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163184 | REC_0007655 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.7 | 68 | female | 1 | 7 | 4.7 | 5 | sotorasib 960 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:58.730611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996103 | REC_0007656 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 12.5 | 69 | female | 0 | 18 | 5.7 | 1 | osimertinib 80 mg daily | 19.8 | false | MSI-H | 2026-03-15T05:35:58.730847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378800 | REC_0007657 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 16.8 | 82 | female | 3 | 2 | 6.8 | 2 | osimertinib 80 mg daily | 22.5 | true | MSI-H | 2026-03-15T05:35:58.731080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545068 | REC_0007658 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 14.8 | 76 | female | 1 | 8 | 5.1 | 2 | entrectinib 600 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:35:58.731365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445500 | REC_0007659 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 4.7 | 65 | male | 0 | 17 | 4.7 | 7 | pembrolizumab 200 mg q3w | 11.6 | true | MSS | 2026-03-15T05:35:58.731601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823457 | REC_0007660 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 9.3 | 56 | female | 1 | 15 | 3.9 | 1 | osimertinib 80 mg daily | 23.6 | true | MSS | 2026-03-15T05:35:58.731833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713142 | REC_0007661 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.2 | 80 | female | 2 | 7 | 2 | 4 | osimertinib 80 mg daily | 20.4 | true | MSS | 2026-03-15T05:35:58.732066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316091 | REC_0007662 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 35 | 6.2 | 72 | female | 1 | 30 | 7 | 2 | carboplatin + paclitaxel + pembrolizumab | 20 | false | MSS | 2026-03-15T05:35:58.732337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573887 | REC_0007663 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 5.7 | 54 | male | 0 | 49 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 21 | false | MSS | 2026-03-15T05:35:58.732574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582847 | REC_0007664 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 9.4 | 68 | female | 0 | 20 | 4.8 | 2 | sotorasib 960 mg daily | 23 | true | MSS | 2026-03-15T05:35:58.732802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306255 | REC_0007665 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.8 | 69 | female | 1 | 30 | 4.3 | 4 | osimertinib 80 mg daily | 9.5 | false | MSI-H | 2026-03-15T05:35:58.733032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586682 | REC_0007666 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 14.9 | 69 | female | 0 | 17 | 4.6 | 5 | pembrolizumab 200 mg q3w | 4.7 | false | MSS | 2026-03-15T05:35:58.733265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648885 | REC_0007667 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.5 | 72 | female | 3 | 22 | 4.2 | 5 | pembrolizumab 200 mg q3w | 8.7 | true | MSS | 2026-03-15T05:35:58.733496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623955 | REC_0007668 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 11.7 | 79 | female | 1 | 18 | 7.3 | 1 | alectinib 600 mg BID | 28 | false | MSS | 2026-03-15T05:35:58.733726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174989 | REC_0007669 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.9 | 67 | female | 0 | 13 | 6.6 | 3 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:58.733954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439820 | REC_0007670 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 2.8 | 66 | female | 0 | 20 | 4.6 | 5 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:58.734182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144902 | REC_0007671 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 10.1 | 81 | female | 1 | 41 | 4.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 29.2 | true | MSI-H | 2026-03-15T05:35:58.734457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947458 | REC_0007672 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7.2 | 70 | female | 2 | 49 | 3.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:35:58.734689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879571 | REC_0007673 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 13.4 | 71 | female | 3 | 15 | 7.5 | 2 | osimertinib 80 mg daily | 19 | false | MSS | 2026-03-15T05:35:58.734924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430862 | REC_0007674 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 16.8 | 78 | female | 2 | 13 | 7.8 | 7 | osimertinib 80 mg daily | 15.7 | false | MSI-H | 2026-03-15T05:35:58.735154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381921 | REC_0007675 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 1.5 | 67 | female | 1 | 7 | 5.2 | 2 | pembrolizumab 200 mg q3w | 24.2 | true | MSS | 2026-03-15T05:35:58.735382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869516 | REC_0007676 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.1 | 79 | female | 2 | 57 | 4.4 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:58.735609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260030 | REC_0007677 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 8.1 | 67 | female | 1 | 55 | 5.5 | 4 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:35:58.735842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688646 | REC_0007678 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.8 | 72 | male | 2 | 13 | 6.5 | 6 | pembrolizumab 200 mg q3w | 11.1 | false | MSS | 2026-03-15T05:35:58.736183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895442 | REC_0007679 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 7.2 | 77 | female | 3 | 7 | 4.2 | 6 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:35:58.736440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499987 | REC_0007680 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 34 | 13 | 71 | female | 2 | 24 | 3 | 0 | sotorasib 960 mg daily | 20 | true | MSI-H | 2026-03-15T05:35:58.736686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885738 | REC_0007681 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 4.9 | 64 | male | 1 | 50 | 5.7 | 2 | pembrolizumab 200 mg q3w | 15.3 | true | MSS | 2026-03-15T05:35:58.736924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217972 | REC_0007682 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.4 | 67 | female | 0 | 25 | 3.6 | 5 | sotorasib 960 mg daily | 7.2 | true | MSS | 2026-03-15T05:35:58.737164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299043 | REC_0007683 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 7.9 | 61 | female | 1 | 14 | 4.2 | 2 | osimertinib 80 mg daily | 21.3 | true | MSS | 2026-03-15T05:35:58.737404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236557 | REC_0007684 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7.2 | 67 | female | 0 | 64 | 6.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.2 | false | MSS | 2026-03-15T05:35:58.737716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532167 | REC_0007685 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 8.9 | 68 | female | 1 | 25 | 3.5 | 1 | sotorasib 960 mg daily | 17.2 | true | MSS | 2026-03-15T05:35:58.737958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384173 | REC_0007686 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 12.2 | 62 | female | 1 | 9 | 4.9 | 6 | osimertinib 80 mg daily | 7.6 | false | MSI-H | 2026-03-15T05:35:58.738198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383303 | REC_0007687 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 13.1 | 60 | male | 0 | 2 | 5 | 1 | osimertinib 80 mg daily | 19.2 | false | MSS | 2026-03-15T05:35:58.738445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644247 | REC_0007688 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 33 | 14.2 | 62 | female | 0 | 13 | 3.6 | 3 | pembrolizumab 200 mg q3w | 18.4 | false | MSS | 2026-03-15T05:35:58.738700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343186 | REC_0007689 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 15 | 8 | 71 | female | 2 | 7 | 5.6 | 5 | pembrolizumab 200 mg q3w | 7.7 | true | MSS | 2026-03-15T05:35:58.738943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736893 | REC_0007690 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 15.7 | 73 | female | 1 | 29 | 3.4 | 2 | osimertinib 80 mg daily | 27.6 | true | MSS | 2026-03-15T05:35:58.739191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307933 | REC_0007691 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6 | 86 | female | 3 | 72 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.7 | true | MSS | 2026-03-15T05:35:58.739446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178438 | REC_0007692 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 15.9 | 74 | female | 0 | 12 | 5.1 | 10 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:58.739701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265188 | REC_0007693 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 15.8 | 65 | male | 1 | 16 | 6.3 | 0 | osimertinib 80 mg daily | 42.9 | false | MSS | 2026-03-15T05:35:58.739956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286978 | REC_0007694 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 14.2 | 56 | female | 1 | 9 | 5.7 | 0 | entrectinib 600 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:58.740263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133681 | REC_0007695 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.6 | 65 | male | 1 | 28 | 3.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.8 | false | MSS | 2026-03-15T05:35:58.740516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459047 | REC_0007696 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 11.3 | 52 | male | 0 | 6 | 6.6 | 2 | osimertinib 80 mg daily | 20.7 | false | MSI-H | 2026-03-15T05:35:58.740766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971167 | REC_0007697 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 15.6 | 69 | female | 0 | 5 | 5.4 | 1 | entrectinib 600 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:58.741170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754723 | REC_0007698 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 8.4 | 63 | female | 1 | 12 | 5.3 | 6 | alectinib 600 mg BID | 10.7 | false | MSS | 2026-03-15T05:35:58.741446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305016 | REC_0007699 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.2 | 72 | female | 2 | 60 | 4 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:58.741698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297021 | REC_0007700 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 7.5 | 65 | male | 1 | 10 | 8.5 | 1 | osimertinib 80 mg daily | 32.1 | false | MSS | 2026-03-15T05:35:58.741944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.